O. M. Akay Et Al. , "Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.," Hematological oncology , vol.39, no.4, pp.498-505, 2021
Akay, O. M. Et Al. 2021. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.. Hematological oncology , vol.39, no.4 , 498-505.
Akay, O. M., Ozbalak, M. M., Pehlivan, M., Yildiz, B., Uzay, A., Yigenoglu, T. N., ... Elverdi, T.(2021). Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.. Hematological oncology , vol.39, no.4, 498-505.
Akay, Olga Et Al. "Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.," Hematological oncology , vol.39, no.4, 498-505, 2021
Akay, Olga M. Et Al. "Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.." Hematological oncology , vol.39, no.4, pp.498-505, 2021
Akay, O. M. Et Al. (2021) . "Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.." Hematological oncology , vol.39, no.4, pp.498-505.
@article{article, author={Olga Meltem Akay Et Al. }, title={Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.}, journal={Hematological oncology}, year=2021, pages={498-505} }